Phenotypes associated with this allele

• Allele Symbol: N4bp1^tm1.2Vmd
• Allele Name: targeted mutation 1.2, Vishva Dixit
• Allele ID: MGI:6490626
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	N4bp1^tm1.2Vmd/N4bp1^tm1.2Vmd	involves: C57BL/6	MGI:6491435

Genotype
MGI:6491435

hm1

• Allelic Composition: N4bp1^tm1.2Vmd/N4bp1^tm1.2Vmd
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased susceptibility to bacterial infection induced morbidity/mortality ( J:297419 )

• mice treated with Streptococcus pneumoniae exhibit increased survival even upon TNF blockage compared with wild-type mice

immune system

increased germinal center B cell number ( J:297419 )

• in the spleen, inguinal lymph nodes and mesenteric lymph nodes at 6 to 7 weeks and more so at 13 to 14 weeks

increased activated T cell number ( J:297419 )

• in the spleen, inguinal lymph nodes and mesenteric lymph nodes at 6 to 7 weeks and more so at 13 to 14 weeks

increased Ly6C high monocyte number ( J:297419 )

• in the spleen, inguinal lymph nodes and mesenteric lymph nodes at 6 to 7 weeks and more so at 13 to 14 weeks

abnormal macrophage physiology ( J:297419 )

• bone marrow-derived macrophages exhibit hyperresponsiveness to TLR1/2, TLR7, or TLR9 with increased production of G-CSF (CSF3), IL6, TNF, and CXCL1 compared with wild-type cells

increased circulating interleukin-6 level ( J:297419 )

• in mice injected with Pam3csk4

increased circulating tumor necrosis factor level ( J:297419 )

• in mice injected with Pam3csk4

increased interleukin-6 secretion ( J:297419 )

• in bone marrow-derived macrophages stimulated with TLR1/2, TLR7, or TLR9

increased tumor necrosis factor secretion ( J:297419 )

• in bone marrow-derived macrophages stimulated with TLR1/2, TLR7, or TLR9

lung inflammation ( J:297419 )

• mild at 13 to 14 weeks with perivascular and peribronchiolar lymphocyte aggregates and increased serum CXCL1 levels

decreased susceptibility to bacterial infection induced morbidity/mortality ( J:297419 )

• mice treated with Streptococcus pneumoniae exhibit increased survival even upon TNF blockage compared with wild-type mice

integument

epidermal hyperplasia ( J:297419 )

• in mice treated with imiquimod

psoriasis ( J:297419 )

• worsened in mice treated with imiquimod

homeostasis/metabolism

increased circulating interleukin-6 level ( J:297419 )

• in mice injected with Pam3csk4

increased circulating tumor necrosis factor level ( J:297419 )

• in mice injected with Pam3csk4

decreased body temperature ( J:297419 )

• in mice injected with Pam3csk4

increased physiological sensitivity to xenobiotic ( J:297419 )

• mice injected with Pam3csk4 exhibit reduced body temperature and increased IL6, TNF, and CXCL1 serum levels compared with wild-type mice

increased susceptibility to injury ( J:297419 )

• exacerbated psoriasis (as measured by worsened serocellular crusting, epidermal hyperplasia, and inflammatory cell infiltration) in mice treated with imiquimod

respiratory system

lung inflammation ( J:297419 )

• mild at 13 to 14 weeks with perivascular and peribronchiolar lymphocyte aggregates and increased serum CXCL1 levels

hematopoietic system

anemia ( J:297419 )

• worsened in mice treated with imiquimod

increased germinal center B cell number ( J:297419 )

• in the spleen, inguinal lymph nodes and mesenteric lymph nodes at 6 to 7 weeks and more so at 13 to 14 weeks

increased activated T cell number ( J:297419 )

• in the spleen, inguinal lymph nodes and mesenteric lymph nodes at 6 to 7 weeks and more so at 13 to 14 weeks

increased Ly6C high monocyte number ( J:297419 )

• in the spleen, inguinal lymph nodes and mesenteric lymph nodes at 6 to 7 weeks and more so at 13 to 14 weeks

abnormal macrophage physiology ( J:297419 )

• bone marrow-derived macrophages exhibit hyperresponsiveness to TLR1/2, TLR7, or TLR9 with increased production of G-CSF (CSF3), IL6, TNF, and CXCL1 compared with wild-type cells